BioPharma Dive30m
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
BioPharma Dive3h
TRex Bio raises $84M to compete in crowded immune drug field
The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...
BioPharma Dive16h
Metsera raises $215M to accelerate obesity drug plans
After Novo Nordisk and Eli Lilly transformed the market for obesity treatment, a flood of drugmakers has jumped in with ...
BioPharma Dive16h
BioNTech to buy Biotheus, gaining control of cancer bispecific
BioNTech is buying into one of the hottest areas of oncology, agreeing to pay $800 million to acquire China-based Biotheus ...
BioPharma Dive23h
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
BioPharma Dive23h
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...